Back to results
US 10,370,718 B2Granted
Use of HLA genetic status to assess or select treatment of celiac disease
AssigneeImmusanT, Inc.
InventorRobert P. Anderson
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of adjusting or selecting a gluten peptide therapy based on the human leukocyte antigen (HLA) genotype, in particular HLA-DQ2.5 homozygosity, of a subject having or suspected of having Celiac disease. Also provided herein are methods of identifying (e.g., diagnosing) a subject, such as a subject having or suspected of having Celiac disease and/or assessing the efficacy of treatment of Celiac disease, e.g. by determining responsiveness to a therapeutic gluten peptide composition or cytokine response, and kits relating thereto.
Claims13
A method, comprising:
- assessing a human leukocyte antigen (HLA) genotype of a subject to determine whether the subject has a homozygous genotype or a heterozygous genotype;
- selecting or adjusting a dose of a gluten peptide treatment for the subject based on the HLA genotype of the subject, and
- administering the selected or adjusted dose of the gluten peptide treatment to the subject, wherein the subject has or is suspected of having Celiac disease, and
- wherein the dose is adjusted or selected for the subject such that the amount is sufficient to provide a therapeutic or physiological effect without causing severe adverse effects.
1 more element
Dependencies are inferred from the claim text.